RecruitingNCT06866652
Evaluating Dyspnea in Autoimmune Myasthenia Gravis "Why am I Short of Breath?"
Sponsor
Institut de Myologie, France
Enrollment
50 participants
Start Date
Apr 8, 2026
Study Type
OBSERVATIONAL
Conditions
Summary
Individuals with MG (IwMG) experience shortness of breath that may be activity-related, occur at rest and even happen during sleep. Dyspnea is a complex, multidimensional and multifactorial symptom involving sensory perception, cognition and emotion. Identifying the cause(s) of dyspnea in MG may assist in finding therapeutic strategies, reducing discomfort, improving QoL and potentially limiting respiratory deterioration and incidence of MG crisis.
Eligibility
Min Age: 18 Years
Inclusion Criteria5
- Age ≥18
- Confirmed diagnosis of autoimmune MG
- Shortness of breath in daily life: score 1 or 2 on the respiration item on the MG- activities of daily living score
- Signed consent form
- Affiliated to or beneficiary of a social security scheme
Exclusion Criteria6
- Known Pregnancy
- Known respiratory disorder (other than MG)
- Recent (within past 4 weeks) respiratory infection
- Current MG crisis or exacerbation (necessitating increase in MG medication \&/or hospital admission)
- No dyspnea - score 0 or 3 on the respiration item on the MG- activities of daily living score
- Severe cognitive impairment/guardianship
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06866652
Related Trials
Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis
NCT0721758712 locations
ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod
NCT072844209 locations
ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis
NCT0729417010 locations
A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases
NCT073041543 locations
Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia Gravis
NCT0641495440 locations